Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dupilumab + unspecified PD-L1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dupilumab | REGN 668|REGN-668|REGN668|SAR 231893|SAR231893|SAR-231893 | Dupilumab is a monoclonal antibody that targets IL-4Ralpha, resulting in decreased IL-4 and IL-13 signaling and potentially leading to decreased tumor cell survival (NCI Drug Dictionary). | ||
| unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05013450 | Phase Ib/II | Dupilumab + unspecified PD-L1 antibody Dupilumab + unspecified PD-1 antibody | Dupilumab_Metastatic NSCLC | Completed | USA | 0 |